Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Active Trials
    3(100%)

    Phase Distribution

    Phase 3
    2
    67%
    Phase 1
    1
    33%

    Phase Distribution

    1

    Early Stage

    0

    Mid Stage

    2

    Late Stage

    Phase Distribution3 total trials
    Phase 1Safety & dosage
    1(33.3%)
    Phase 3Large-scale testing
    2(66.7%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 0 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    3

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Active(3)

    Detailed Status

    Recruiting2
    Active, not recruiting1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    3
    Success Rate
    N/A
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 11 (33.3%)
    Phase 32 (66.7%)

    Trials by Status

    active_not_recruiting133%
    recruiting267%

    Recent Activity

    3 active trials
    Showing 3 of 3
    active_not_recruitingphase_3

    The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer

    NCT01706939
    recruitingphase_1

    Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

    NCT06005324
    recruitingphase_3

    Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma

    NCT06912698

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT01706939Phase 3

    The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer

    Active Not Recruiting
    NCT06005324Phase 1

    Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

    Recruiting
    NCT06912698Phase 3

    Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma

    Recruiting

    All 3 trials loaded

    Drug Details

    Intervention Type
    Radiation
    Total Trials
    3